Recombinant Human ZBTB17 protein

中文名： 锌指和BTB结构域的蛋白17(ZBTB17)重组蛋白
别名： ZBTB17；MIZ1；ZNF151；ZNF60；Zinc finger and BTB domain-containing protein 17

货号: PA1000-4966

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	ZBTB17
Uniprot No	Q13105
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-188aa
氨基酸序列	MGSSHHHHHHSSGLVPRGSHMDFPQHSQHVLEQLNQQRQLGLLCDCTFVV DGVHFKAHKAVLAACSEYFKMLFVDQKDVVHLDISNAAGLGQVLEFMYTA KLSLSPENVDDVLAVATFLQMQDIITACHALKSLAEPATSPGGNAEALAT EGGDKRAKEEKVATSTLSRLEQAGRSTPIGPSRDLKEERGGQAQSAASGA EQTEKADA
预测分子量	22 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇涉及ZBTB17重组蛋白研究的参考文献摘要概括：

1. **文献名称**：*ZBTB17 (MIZ1) is a dual regulator of cell proliferation and DNA damage response*

**作者**：Liu, X., et al.

**摘要**：研究利用重组ZBTB17蛋白，发现其通过结合特定DNA序列调控细胞周期基因(如CDKN1A)，并揭示其在DNA损伤修复通路中与ATM激酶的相互作用，表明其双重调控功能。

2. **文献名称**：*Structural basis of ZBTB17-DNA recognition and its role in MYC transcriptional repression*

**作者**：Wang, Y., et al.

**摘要**：通过重组表达纯化人源ZBTB17蛋白，解析其锌指结构域与MYC启动子结合的晶体结构，证明其通过抑制MYC转录参与肿瘤抑制机制。

3. **文献名称**：*Recombinant ZBTB17 protein inhibits NF-κB signaling by competing with p65 subunit binding*

**作者**：Chen, L., et al.

**摘要**：体外实验显示，重组ZBTB17蛋白通过结合NF-κB靶基因的κB位点，阻断p65亚基的募集，从而抑制炎症因子诱导的NF-κB通路激活。

(注：以上文献信息为示例性概括，实际引用需核对真实文献。)

背景信息

ZBTB17 (Zinc Finger and BTB Domain-Containing Protein 17), also known as MIZ1 or ZNF151. is a member of the ZBTB family of transcription factors characterized by zinc finger motifs and a BTB/POZ domain. It plays a dual role in transcriptional regulation, acting as both a repressor and activator depending on cellular context and binding partners. Structurally, its N-terminal BTB domain facilitates protein-protein interactions, while the C-terminal zinc fingers mediate sequence-specific DNA binding, often targeting promoters of genes involved in cell cycle control, differentiation, and stress responses.

A key feature of ZBTB17 is its interaction with MYC, a well-known oncoprotein. This complex can either co-activate or repress target genes, influencing cell proliferation, apoptosis, and metabolic pathways. For example, ZBTB17-MYC interactions may suppress cell cycle inhibitors like p21 (CDKN1A) to promote growth, while ZBTB17 alone can activate pro-differentiation or tumor-suppressive genes. Dysregulation of ZBTB17 has been implicated in cancers, including leukemia, breast cancer, and hepatocellular carcinoma, where its expression is frequently altered due to mutations, deletions, or epigenetic changes. Paradoxically, it may act as a tumor suppressor in some contexts but contribute to oncogenesis in others.

Recombinant ZBTB17 protein is widely used to study its structural and functional properties. Produced via expression systems like *E. coli* or mammalian cells, it enables *in vitro* assays to map DNA-binding sites, analyze protein interactions (e.g., with MYC or chromatin modifiers), and screen for therapeutic compounds. Its role in MYC-driven cancers makes it a potential target for drug development, particularly in disrupting oncogenic MYC-ZBTB17 complexes. Ongoing research aims to clarify its context-dependent mechanisms and therapeutic potential in precision oncology.